Component Identity Confirmation (21 CFR 111.75)
Dietary ingredient identity testing, other component specifications and qualified supplier-certificate reliance are distinct pre-use controls under 21 CFR 111.70 and 111.75.

On this page · 12 sections
- 1Identity is a pre-use component decision
- 2Distinguish dietary ingredients from other components
- 3Treat an FDA petition as an actual exception
- 4Select an appropriate method for the actual material
- 5Design sampling to preserve lot identity
- 6Qualify a certificate-of-analysis reliance pathway
- 7Reconfirm reliability rather than set-and-forget approval
- 8Keep identity and other specifications separate
- 9Respond to an identity failure without hiding the result
- 10Assign duties at receipt, laboratory and QC review
- 11Audit the decision rather than the folder name
- 12Preserve the basis when the record is transferred
How does Component Identity Confirmation (21 CFR 111.75) apply to your shop floor?
Pick your industry and scale — Ask V5 rewrites the definition in your context, gives a worked example, and shows what V5 does on day one.
01Identity is a pre-use component decision
Section 111.75(a) addresses what a dietary supplement manufacturer must do before using a component. It separates the identity of a component that is a dietary ingredient from the identity of other components and other applicable component specifications. That separation is essential: the option to rely on a qualified supplier's certificate of analysis does not generally replace the dietary-ingredient identity test required by paragraph (a)(1)(i).
Section 111.70(b) establishes the component specifications: identity, specifications needed to ensure finished-supplement purity, strength and composition, and limits on contamination that may adulterate the finished batch. Identity is therefore one part of acceptance, not shorthand for all suitability decisions. A material can match its claimed identity and still fail a relevant purity, potency or contamination requirement.
The requirement concerns the actual component before use, not merely whether a supplier appears on an approved list. Receipt inspection, purchase-order matching, supplier qualification and laboratory identity evidence answer different questions. Build the acceptance decision so those questions remain separate and their results can be retrieved. The dietary supplement operations guide provides wider manufacturing context, but the rule and approved material specifications govern the actual decision.
02Distinguish dietary ingredients from other components
For a component that is a dietary ingredient, section 111.75(a)(1)(i) requires at least one appropriate test or examination to verify identity unless FDA grants an exemption under the petition mechanism. The text of paragraph (a)(1)(ii) compares a proposed alternative with the assurance provided by 100 percent identity testing. Do not recast supplier confidence, previous passing deliveries or a commercial certificate as an automatic regulatory exemption.
For other components and for other applicable component specifications, paragraph (a)(2) allows appropriate tests or examinations or reliance on a supplier certificate under stated conditions. An excipient identity decision and a dietary ingredient identity decision can therefore follow different permitted evidence paths. A firm's material classification must reflect the component's actual role and applicable definition rather than a convenient purchasing category.
Document the acceptance path in the material specification or linked procedure. The receiving and QC teams should know which evidence is mandatory before a lot becomes eligible for use. If a premix contains dietary ingredients, assess how the applicable identity requirement can be appropriately demonstrated for the material rather than assuming that a supplier's generic description resolves every constituent identity issue.
03Treat an FDA petition as an actual exception
Section 111.75(a)(1)(ii) permits a petition under 21 CFR 10.30 seeking exemption from the identity-testing requirement. The petition must include a scientific rationale and supporting data and information for alternative testing that does not materially diminish assurance of identity compared with 100 percent identity testing for material from specified suppliers. This is an agency decision process, not an internal risk assessment that a manufacturer can approve for itself.
If FDA grants a petition, the manufacturer must conduct the tests and examinations under the terms FDA specifies. Keep the decision, scope, supplier identities and conditions available to personnel responsible for acceptance. A petition submitted but not granted is not an exemption. Likewise, a decision for one material-and-supplier situation should not be extended to unrelated materials without an applicable basis.
The practical control is a clearly identified exception register linked to the affected specifications. Review whether receipt, sampling and release procedures implement the granted terms. This article does not identify any firm's granted petition or suggest that a petition will be approved. In the absence of an applicable FDA exemption, plan the required identity test or examination before use.
04Select an appropriate method for the actual material
The word 'appropriate' is substantive. Section 111.75(h) requires tests and examinations used to determine whether specifications are met to be appropriate and scientifically valid methods. A familiar instrument or rapid screening technique is not automatically suitable for every botanical, blend, extract or processed ingredient. Method suitability depends on what identity must be distinguished and the material's actual characteristics.
Consider specificity, the relevant reference material, sample preparation, interference from processing or other constituents, and the ability to distinguish plausible substitutions. A visual examination can provide useful information but should not be assumed adequate where relevant identity distinctions cannot be observed. A spectral match may need a justified reference library and acceptance criterion. These are method-selection considerations, not regulatory endorsements of a named technique.
Record the method identifier and version, acceptance criterion, sample identity, result, analyst or examiner identity and review status according to the applicable procedure. Preserve the underlying evidence necessary to interpret the result. A field reading 'identity passed' without a retrievable basis may not allow a later reviewer to assess what was tested or how the decision was reached.
05Design sampling to preserve lot identity
Before a component is used, its identity evidence must be linked to the received material. The rule should not be paraphrased as testing every container using one universal technique; nor should it be diluted into testing an occasional supplier delivery regardless of the actual lot. The firm's sampling procedure needs an appropriate, justified connection between the sample, received lot and acceptance decision.
Define the incoming lot identification, supplier lot reference, container population, sample collection procedure and sample handling controls. Keep multiple lots separate during receipt and sampling. If several containers bear inconsistent supplier identifiers, investigate rather than merge them into a convenient internal lot. A sound analytical method cannot correct an untraceable sample or a sample taken from the wrong material.
Control the sampled material's status while results are pending. Sampling does not itself authorize use. Where material is split, moved or relabeled, preserve its relationship to the acceptance evidence. Check that the production team can identify which lot is eligible and which remains held. These are practical status controls; no particular warehouse software capability is asserted here.
06Qualify a certificate-of-analysis reliance pathway
Section 111.75(a)(2)(ii) sets explicit conditions for supplier-certificate reliance. First qualify the supplier by establishing reliability of its certificate through confirmation of supplier test or examination results. The certificate must describe the methods, limits and actual results. Maintain qualification documentation, periodically reconfirm the certificate, and obtain QC review and approval of the qualification and requalification basis.
These conditions are more specific than collecting a PDF or a supplier questionnaire. A statement such as 'conforms' without actual results and method or limit information should be evaluated against the rule's requirements rather than automatically accepted. Qualification should identify what was confirmed, which materials or specifications are covered, and why the supplier's evidence is reliable for that intended reliance.
The supplier qualification worksheet can help organize the assessment, while the sample supplier approval record illustrates a decision record. Neither is evidence that a real supplier has been qualified. Use the actual confirmation results, supplier information and QC decision for the firm's materials. Do not infer product conformity from a sample document's appearance.
07Reconfirm reliability rather than set-and-forget approval
The regulation requires periodic reconfirmation but does not supply a universal interval for every supplier and component. Establish a justified programme appropriate to the material, reliance scope and supplier performance. Describe what triggers additional review, such as method changes, unexplained result differences, changed manufacturing location, identity discrepancies or a relevant complaint. These are suggested assessment triggers, not a mandatory exhaustive list.
A supplier approval can remain current administratively while its certificate basis has become unsuitable. Check whether the analytical method, acceptance limits and supplied grade remain consistent with the qualification evidence. If the material or process changes, evaluate the effect on reliance. An old approval date alone does not answer whether the current certificate remains reliable.
Record reconfirmation results and the QC approval of requalification. Where a discrepancy is found, contain affected material, determine the scope of potentially unreliable certificates, and decide what testing or other action is required. Do not restore reliance simply because a replacement certificate contains a passing number. Preserve the reason for the discrepancy and the assessment supporting the next decision.
08Keep identity and other specifications separate
An identity result should not be represented as a release certificate for every component attribute. Section 111.70(b) requires other component specifications where necessary for the finished supplement and contamination limits. Section 111.75(a)(2) addresses determining whether those applicable specifications are met. A material acceptance checklist should therefore distinguish identity evidence from the evidence supporting the other applicable requirements.
For example, identifying a botanical ingredient does not by itself establish its contaminant levels or the amount of a specified constituent. Conversely, a contaminant result does not establish identity. Which attributes apply, how they are assessed and which evidence path is permitted must be justified for the actual material. Avoid substituting a generic 'quality passed' field for these separate decisions.
Quality-control personnel review the relevant specifications and evidence under Part 111 responsibilities. The manufacturing team must use eligible materials and document actual component use in the batch production record. Approval at receipt and traceability during dispensing are connected controls, but they are not interchangeable. A released lot can still be misidentified during staging or addition.
09Respond to an identity failure without hiding the result
An inconclusive result requires an assessed response under the firm's applicable material-review procedures. Hold the affected material and preserve the original observations. Review the sample identity, method performance, reference material, handling and supplier information before determining what the result means. An analytical error is possible, but it must be established with evidence rather than assumed because the supplier is familiar. If the component fails its identity specification, section 111.77(b) requires QC personnel to reject it, and it must not be used in manufacturing. Do not treat an established identity failure as a pending result or apply the other-specification treatment pathway to it.
Retesting should follow an authorized, scientifically justified investigation approach. Repeating tests until one passes can obscure a genuine substitution or sample problem. Preserve the original failing or inconclusive evidence and explain each additional examination. Determine whether other incoming lots or manufactured batches may be affected by the same discrepancy and document the assessed scope.
If material was used before the issue was recognized, connect it to the affected batch history and involve QC in containment and disposition. Do not treat a corrected purchase description as resolution of a manufactured-product risk. This article does not prescribe a universal recall decision; it explains why a reliable lot relationship and documented assessment are needed to make the applicable decision.
10Assign duties at receipt, laboratory and QC review
Receiving personnel identify the delivery, supplier lot and container condition and prevent uncontrolled use while acceptance is pending. Sampling personnel maintain the sample-to-lot relationship. Analysts or examiners perform the approved method and preserve its evidence. Supplier-quality personnel develop and maintain the qualification basis. QC reviews and approves the applicable acceptance and supplier-qualification decisions.
The firm can assign these tasks differently, but should make the handoffs explicit. A receiving employee should not assume that the presence of a certificate proves QC release. A laboratory result should not be interpreted as the final acceptance decision if other specifications remain unresolved. Purchasing should not change the material's approval status simply because production urgently needs stock.
Train personnel on the dietary-ingredient distinction and the limits of certificate reliance. Include how to handle a missing method reference, different supplier grade, uncertain container identity and a delayed result. A practical exercise is to follow one incoming lot from receipt to authorized use and ask each role which evidence it creates and which decision it is permitted to make.
11Audit the decision rather than the folder name
For an inspection or internal audit, choose one dietary ingredient lot and retrieve its identity evidence before use. Identify the method, sample relationship, acceptance criterion, actual result and applicable review. Then choose a component specification accepted through supplier-certificate reliance and retrieve the supplier confirmation evidence, certificate contents, periodic reconfirmation and QC approval. These tests assess two different regulatory pathways.
Ask whether every certificate relied upon contains methods, limits and actual results, whether qualification covers the current supplied material, and whether the reconfirmation programme is actually performed. Check an exception lot as well as a normal lot. Audit questions should expose missing evidence or ambiguous decisions without presuming a particular company's failure or claiming a assured inspection outcome.
Typical vulnerabilities to examine include using a supplier certificate instead of mandatory dietary-ingredient identity testing, confusing a submitted petition with an exemption, testing an untraceable sample, accepting nominal results without methods or limits, and maintaining supplier approval without periodic confirmation. The dietary supplement sector page provides commercial context; manufacturer responsibilities and scientifically valid acceptance evidence remain with the manufacturer.
12Preserve the basis when the record is transferred
When acceptance evidence is transferred between systems or organizations, keep the sample and lot references together with the result and review status. A readable summary is helpful, but removing the method, acceptance limit or source identification can make the decision difficult to reconstruct. Assess what must remain available for the applicable record-retention period.
Test retrieval using a historical lot, not only the current approval screen. Confirm that a reviewer can distinguish the supplier's original certificate from the manufacturer's confirmation result and the QC decision relying upon it. This distinction matters when a supplier later revises a certificate: preserve the earlier evidence and the assessment of the revision rather than replacing the original file without explanation.
Frequently asked questions
Q.Can a supplier CoA replace dietary ingredient identity testing?+
Generally no. Section 111.75(a)(1)(i) requires an appropriate identity test or examination unless FDA grants an applicable petition exemption. Certificate reliance for other components and other specifications has separate conditions.
Q.Does Part 111 specify one reconfirmation frequency?+
The cited provision requires periodic reconfirmation, not a universal interval. The firm should establish and document an appropriate programme and QC-approved basis for its reliance.
Primary sources
Further reading
Want to see how Component Identity Confirmation (21 CFR 111.75) could fit into your own records and workflows? Explore the related V5 pages or talk to our team about what applies to your operation.
